Register to ALFA

Publications

From the ALFA group

Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use.

Haematologica. 2020 Dec 10;Online ahead of print. doi: 10.3324/haematol.2020.260133

15/03/2021

Lesieur A, Thomas X, Nibourel O, Boissel N, Fenwarth L, De Botton S, Fournier E, Celli-Lebras K, Raffoux E, Recher C, Lambert J, Berthon C, Pigneux A, Itzykson R, Turlure P, Pautas C, Vargaftig J, Preudhomme C, Dombret H, Duployez N

Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia.

Bone Marrow Transplant. 2021 Feb 9. doi: 10.1038/s41409-020-01207-4. Online ahead of print.

12/03/2021

Pautas C, Raffoux E,Lambert J, Legrand O, Chantepie S, Gastaud L, Marolleau JP, Thomas X, Turlure P, Benner RJ, Vandendries E, Gogat K, Dombret H, Castaigne S

A Personalized Approach to Guide Allogeneic Stem Cell Transplantation in Younger Adults with Acute Myeloid Leukemia.

Blood. 2021 Jan 28;137(4):524-532. doi: 10.1182/blood.2020005524.

06/11/2020

Fenwarth L, Thomas X, de Botton S, Duployez N, Bourhis JH, Lesieur A, Fortin G, Meslin PA, Yakoub-Agha I, Sujobert P, Dumas PY, Récher C, Lebon D, Berthon C, Michallet M, Pigneux A, Nguyen S, Chantepie SP, Vey N, Raffoux E, Celli-Lebras K, Gardin CJ, Lambert J, Malfuson JV, Caillot D, Maury S, Ducourneau B, Turlure P, Lemasle E, Pautas C, Chevret S, Terré C, Boissel N, Socie G, Dombret H, Preudhomme C, Itzykson RA.

Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment.

Int J Mol Sci. 2020 Aug 6-21(16):5626. doi: 10.3390/ijms21165626.

06/11/2020

Fenwarth L, Fournier E, Cheok M, Boyer T, Gonzales F, Castaigne S, Boissel N, Lambert J, Dombret H, Preudhomme C, Duployez N.

Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results.

Blood Adv. 2020 May 12-4(9):1942-1949. doi: 10.1182/bloodadvances.2019001349.

06/11/2020

Gardin C, Pautas C, Fournier E, Itzykson R, Lemasle E, Bourhis JH, Adès L, Marolleau JP, Malfuson JV, Gastaud L, Raffoux E, Lambert J, Braun T, Thomas X, Chantepie S, Cluzeau T, de Botton S, Berthon C, Boissel N, Duployez N, Terré C, Peffault de Latour R, Michallet M, Celli-Lebras K, Preudhomme C, Dombret H.

Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia.

Blood. 2020 Feb 20-135(8):542-546. doi: 10.1182/blood.2019003471.

06/11/2020

Fournier E, Duployez N, Ducourneau B, Raffoux E, Turlure P, Caillot D, Thomas X, Marceau-Renaut A, Chantepie S, Malfuson JV, Lemasle E, Cheok M, Celli-Lebras K, Guerin E, Terré C, Lambert J, Pautas C, Dombret H, Castaigne S, Preudhomme C, Boissel N.

Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex Karyotype.

Cancers (Basel). 2019 Dec 30-12(1):88. doi: 10.3390/cancers12010088.

06/11/2020

Fenwarth L, Duployez N, Thomas X, Boissel N, Geffroy S, Marceau-Renaut A, Caillot D, Raffoux E, Lemasle E, Marolleau JP, Berthon C, Cheok MH, Peyrouze P, Pigneux A, Vey N, Celli-Lebras K, Terré C, Preudhomme C, Dombret H.

Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts.

J Clin Oncol. 2019 Oct 10-37(29):2632-2642. doi: 10.1200/JCO.19.00416. Epub 2019 Aug 20.

06/11/2020

Angenendt L, Röllig C, Montesinos P, Martínez-Cuadrón D, Barragan E, García R, Botella C, Martínez P, Ravandi F, Kadia T, Kantarjian HM, Cortes J, Juliusson G, Lazarevic V, Höglund M, Lehmann S, Recher C, Pigneux A, Bertoli S, Dumas PY, Dombret H, Preudhomme C, Micol JB, Terré C, Ráčil Z, Novák J, Žák P, Wei AH, Tiong IS, Wall M, Estey E, Shaw C, Exeler R, Wagenführ L, Stölzel F, Thiede C, Stelljes M, Lenz G, Mikesch JH, Serve H, Ehninger G, Berdel WE, Kramer M, Krug U, Schliemann C.

Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial.

Haematologica. 2019 Jan-104(1):113-119. doi: 10.3324/haematol.2018.188888. Epub 2018 Aug 3.

06/11/2020

Lambert J, Pautas C, Terré C, Raffoux E, Turlure P, Caillot D, Legrand O, Thomas X, Gardin C, Gogat-Marchant K, Rubin SD, Benner RJ, Bousset P, Preudhomme C, Chevret S, Dombret H, Castaigne S.

Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia.

Blood. 2018 Jul 12-132(2):187-196. doi: 10.1182/blood-2018-03-837781. Epub 2018 Apr 24.

06/11/2020

Itzykson R, Duployez N, Fasan A, Decool G, Marceau-Renaut A, Meggendorfer M, Jourdan E, Petit A, Lapillonne H, Micol JB, Cornillet-Lefebvre P, Ifrah N, Leverger G, Dombret H, Boissel N, Haferlach T, Preudhomme C.

Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group.

Haematologica. 2018 May-103(5):822-829. doi: 10.3324/haematol.2017.183525. Epub 2018 Feb 22.

06/11/2020

Ferret Y, Boissel N, Helevaut N, Madic J, Nibourel O, Marceau-Renaut A, Bucci M, Geffroy S, Celli-Lebras K, Castaigne S, Thomas X, Terré C, Dombret H, Preudhomme C, Renneville A.

SNP-array lesions in core binding factor acute myeloid leukemia.

Oncotarget. 2018 Jan 8-9(5):6478-6489. doi: 10.18632/oncotarget.24031. eCollection 2018 Jan 19.

06/11/2020

Duployez N, Boudry-Labis E, Roumier C, Boissel N, Petit A, Geffroy S, Helevaut N, Celli-Lebras K, Terré C, Fenneteau O, Cuccuini W, Luquet I, Lapillonne H, Lacombe C, Cornillet P, Ifrah N, Dombret H, Leverger G, Jourdan E, Preudhomme C.

Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission.

J Clin Oncol. 2017 Apr 10-35(11):1223-1230. doi: 10.1200/JCO.2016.70.4551. Epub 2017 Feb 21.

06/11/2020

Thomas X, de Botton S, Chevret S, Caillot D, Raffoux E, Lemasle E, Marolleau JP, Berthon C, Pigneux A, Vey N, Reman O, Simon M, Recher C, Cahn JY, Hermine O, Castaigne S, Celli-Lebras K, Ifrah N, Preudhomme C, Terré C, Dombret H.

Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA.

Leuk Res. 2017 Mar-54:12-16. doi: 10.1016/j.leukres.2017.01.002. Epub 2017 Jan 5.

06/11/2020

Wang L, Raffoux E, Thomas X, Yakoub-Agha I, Bouhris JH, de Botton S, Michallet M, Quoc SN, Chantepie S, Deconinck E, Caillot D, Turlure P, Vigouroux S, Pigneux A, Huynh A, Malfuson JV, Loschi M, Socie G, Dombret H, de la Tour RP, Cluzeau T.

A 17-gene stemness score for rapid determination of risk in acute leukaemia.

Nature. 2016 Dec 15-540(7633):433-437. doi: 10.1038/nature20598. Epub 2016 Dec 7.

06/11/2020

Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, Arruda A, Popescu A, Gupta V, Schimmer AD, Schuh AC, Yee KW, Bullinger L, Herold T, Görlich D, Büchner T, Hiddemann W, Berdel WE, Wörmann B, Cheok M, Preudhomme C, Dombret H, Metzeler K, Buske C, Löwenberg B, Valk PJ, Zandstra PW, Minden MD, Dick JE, Wang JC.

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.

J Clin Oncol. 2017 Jan 10-35(2):185-193. doi: 10.1200/JCO.2016.67.1875. Epub 2016 Nov 14.

06/11/2020

Balsat M, Renneville A, Thomas X, de Botton S, Caillot D, Marceau A, Lemasle E, Marolleau JP, Nibourel O, Berthon C, Raffoux E, Pigneux A, Rodriguez C, Vey N, Cayuela JM, Hayette S, Braun T, Coudé MM, Terre C, Celli-Lebras K, Dombret H, Preudhomme C, Boissel N.

Copy-number analysis identified new prognostic marker in acute myeloid leukemia.

Leukemia. 2017 Mar-31(3):555-564. doi: 10.1038/leu.2016.265. Epub 2016 Sep 30.

06/11/2020

Nibourel O, Guihard S, Roumier C, Pottier N, Terre C, Paquet A, Peyrouze P, Geffroy S, Quentin S, Alberdi A, Abdelali RB, Renneville A, Demay C, Celli-Lebras K, Barbry P, Quesnel B, Castaigne S, Dombret H, Soulier J, Preudhomme C, Cheok MH.

Comprehensive mutational profiling of core binding factor acute myeloid leukemia.

Blood. 2016 May 19-127(20):2451-9. doi: 10.1182/blood-2015-12-688705. Epub 2016 Mar 15.

06/11/2020

Duployez N, Marceau-Renaut A, Boissel N, Petit A, Bucci M, Geffroy S, Lapillonne H, Renneville A, Ragu C, Figeac M, Celli-Lebras K, Lacombe C, Micol JB, Abdel-Wahab O, Cornillet P, Ifrah N, Dombret H, Leverger G, Jourdan E, Preudhomme C.

The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.

Blood. 2016 Apr 28-127(17):2157-60. doi: 10.1182/blood-2016-01-689976. Epub 2016 Feb 29.

06/11/2020

Olombel G, Guerin E, Guy J, Perrot JY, Dumezy F, de Labarthe A, Bastie JN, Legrand O, Raffoux E, Plesa A, Wagner-Ballon O, Cornet E, Salaun V, Preudhomme C, Thomas X, Pautas C, Chantepie S, Turlure P, Castaigne S, Dombret H, Feuillard J.

IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.

Oncotarget. 2015 Dec 8-6(39):42345-53. doi: 10.18632/oncotarget.5645.

06/11/2020

Debarri H, Lebon D, Roumier C, Cheok M, Marceau-Renaut A, Nibourel O, Geffroy S, Helevaut N, Rousselot P, Gruson B, Gardin C, Chretien ML, Sebda S, Figeac M, Berthon C, Quesnel B, Boissel N, Castaigne S, Dombret H, Renneville A, Preudhomme C.

Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.

Haematologica. 2016 Mar-101(3):328-35. doi: 10.3324/haematol.2015.131946. Epub 2015 Dec 3.

06/11/2020

Willekens C, Blanchet O, Renneville A, Cornillet-Lefebvre P, Pautas C, Guieze R, Ifrah N, Dombret H, Jourdan E, Preudhomme C, Boissel N - French AML Intergroup.

Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group.

Leuk Res. 2015 Dec-39(12):1443-7. doi: 10.1016/j.leukres.2015.09.021. Epub 2015 Oct 9.

06/11/2020

Smol T, Nibourel O, Marceau-Renaut A, Celli-Lebras K, Berthon C, Quesnel B, Boissel N, Terré C, Thomas X, Castaigne S, Dombret H, Preudhomme C, Renneville A.

Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia.

Oncotarget. 2015 Sep 8-6(26):22812-21. doi: 10.18632/oncotarget.4333.

06/11/2020

Bibault JE, Figeac M, Hélevaut N, Rodriguez C, Quief S, Sebda S, Renneville A, Nibourel O, Rousselot P, Gruson B, Dombret H, Castaigne S, Preudhomme C.

Unlike ASXL1 and ASXL2 mutations, ASXL3 mutations are rare events in acute myeloid leukemia with t(8-21).

Leuk Lymphoma. 2016-57(1):199-200. doi: 10.3109/10428194.2015.1037754. Epub 2015 May 15.

06/11/2020

Duployez N, Micol JB, Boissel N, Petit A, Geffroy S, Bucci M, Lapillonne H, Renneville A, Leverger G, Ifrah N, Dombret H, Abdel-Wahab O, Jourdan E, Preudhomme C.

Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells.

Blood. 2015 May 28-125(22):3447-54. doi: 10.1182/blood-2014-11-612416. Epub 2015 Mar 23.

06/11/2020

El Hajj H, Dassouki Z, Berthier C, Raffoux E, Ades L, Legrand O, Hleihel R, Sahin U, Tawil N, Salameh A, Zibara K, Darwiche N, Mohty M, Dombret H, Fenaux P, de Thé H, Bazarbachi A.

Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial.

Haematologica. 2015 Jun-100(6):780-5. doi: 10.3324/haematol.2014.114884. Epub 2015 Feb 24.

06/11/2020

Boissel N, Renneville A, Leguay T, Lefebvre PC, Recher C, Lecerf T, Delabesse E, Berthon C, Blanchet O, Prebet T, Pautas C, Chevallier P, Leprêtre S, Girault S, Bonmati C, Guièze R, Himberlin C, Randriamalala E, Preudhomme C, Jourdan E, Dombret H, Ifrah N.

Classification of CEBPA mutated acute myeloid leukemia by GATA2 mutations.

Am J Hematol. 2015 May-90(5):E93-4. doi: 10.1002/ajh.23949. Epub 2015 Feb 17.

06/11/2020

Marceau-Renaut A, Guihard S, Castaigne S, Dombret H, Preudhomme C, Cheok M.

Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia.

Haematologica. 2015 May-100(5):e196-9. doi: 10.3324/haematol.2014.115576. Epub 2014 Dec 31.

06/11/2020

Peterlin P, Renneville A, Ben Abdelali R, Nibourel O, Thomas X, Pautas C, de Botton S, Raffoux E, Cayuela JM, Boissel N, Terré C, Celli-Lebras K, Castaigne S, Preudhomme C, Gardin C, Dombret H.

MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin.

Oncotarget. 2014 Aug 15-5(15):6280-8. doi: 10.18632/oncotarget.2196.

06/11/2020

Lambert J, Lambert J, Nibourel O, Pautas C, Hayette S, Cayuela JM, Terré C, Rousselot P, Dombret H, Chevret S, Preudhomme C, Castaigne S, Renneville A.

Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup.

Blood. 2014 Aug 21-124(8):1312-9. doi: 10.1182/blood-2014-01-549212. Epub 2014 Jul 8.

06/11/2020

Hospital MA, Prebet T, Bertoli S, Thomas X, Tavernier E, Braun T, Pautas C, Perrot A, Lioure B, Rousselot P, Tamburini J, Cluzeau T, Konopacki J, Randriamalala E, Berthon C, Gourin MP, Recher C, Cahn JY, Ifrah N, Dombret H, Boissel N.

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.

Lancet Oncol. 2014 Aug-15(9):986-96. doi: 10.1016/S1470-2045(14)70281-5. Epub 2014 Jul 6.

06/11/2020

Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, Estey EH, Dombret H, Chevret S, Ifrah N, Cahn JY, Récher C, Chilton L, Moorman AV, Burnett AK.

Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8-21)/RUNX1-RUNX1T1 chromosomal translocations.

Blood. 2014 Aug 28-124(9):1445-9. doi: 10.1182/blood-2014-04-571018. Epub 2014 Jun 27.

06/11/2020

Micol JB, Duployez N, Boissel N, Petit A, Geffroy S, Nibourel O, Lacombe C, Lapillonne H, Etancelin P, Figeac M, Renneville A, Castaigne S, Leverger G, Ifrah N, Dombret H, Preudhomme C, Abdel-Wahab O, Jourdan E.

Minimal residual disease monitoring in t(8-21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA.

Am J Hematol. 2014 Jun-89(6):610-5. doi: 10.1002/ajh.23696. Epub 2014 Mar 8.

06/11/2020

Duployez N, Nibourel O, Marceau-Renaut A, Willekens C, Helevaut N, Caillault A, Villenet C, Celli-Lebras K, Boissel N, Jourdan E, Dombret H, Figeac M, Preudhomme C, Renneville A.

Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.

Am J Hematol. 2014 Apr-89(4):399-403. doi: 10.1002/ajh.23653. Epub 2014 Mar 7.

06/11/2020

Pilorge S, Rigaudeau S, Rabian F, Sarkozy C, Taksin AL, Farhat H, Merabet F, Ghez S, Raggueneau V, Terré C, Garcia I, Renneville A, Preudhomme C, Castaigne S, Rousselot P.

Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial.

Oncotarget. 2014 Feb 28-5(4):916-32. doi: 10.18632/oncotarget.1536.

06/11/2020

Renneville A, Abdelali RB, Chevret S, Nibourel O, Cheok M, Pautas C, Duléry R, Boyer T, Cayuela JM, Hayette S, Raffoux E, Farhat H, Boissel N, Terre C, Dombret H, Castaigne S, Preudhomme C.

Azacitidine in untreated acute myeloid leukemia: a report on 149 patients.

Am J Hematol. 2014 Apr-89(4):410-6. doi: 10.1002/ajh.23654. Epub 2014 Feb 6.

06/11/2020

Thépot S, Itzykson R, Seegers V, Recher C, Raffoux E, Quesnel B, Delaunay J, Cluzeau T, Marfaing Koka A, Stamatoullas A, Chaury MP, Dartigeas C, Cheze S, Banos A, Morel P, Plantier I, Taksin AL, Marolleau JP, Pautas C, Thomas X, Isnard F, Beve B, Chait Y, Guerci A, Vey N, Dreyfus F, Ades L, Ifrah N, Dombret H, Fenaux P, Gardin C- Groupe Francophone des Myélodysplasies (GFM), Acute Leukemia French Association (ALFA)- Groupe Ouest-Est des Leucémies Aiguës- Maladies du Sang (GOELAMS).

Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.

J Clin Oncol. 2014 Feb 1-32(4):297-305. doi: 10.1200/JCO.2013.50.2047. Epub 2013 Dec 16.

06/11/2020

Janin M, Mylonas E, Saada V, Micol JB, Renneville A, Quivoron C, Koscielny S, Scourzic L, Forget S, Pautas C, Caillot D, Preudhomme C, Dombret H, Berthon C, Barouki R, Rabier D, Auger N, Griscelli F, Chachaty E, Leclercq E, Courtier MH, Bennaceur-Griscelli A, Solary E, Bernard OA, Penard-Lacronique V, Ottolenghi C, de Botton S.

Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification.

Haematologica. 2014 Feb-99(2):308-13. doi: 10.3324/haematol.2013.092072. Epub 2013 Oct 4.

06/11/2020

Wetzler M, Mrózek K, Kohlschmidt J, Dombret H, Döhner H, Pilorge S, Krug U, Carroll AJ, Larson RA, Marcucci G, Hiddemann W, Büchner T, Bloomfield CD.

Outcome of older patients with acute myeloid leukemia in first relapse.

Am J Hematol. 2013 Sep-88(9):758-64. doi: 10.1002/ajh.23498. Epub 2013 Aug 7.

06/11/2020

Sarkozy C, Gardin C, Gachard N, Merabet F, Turlure P, Malfuson JV, Pautas C, Micol JB, Thomas X, Quesnel B, Celli-Lebras K, Preudhomme C, Terré C, Fenaux P, Chevret S, Castaigne S, Dombret H.

Neurofibromatosis-1 gene deletions and mutations in de novo adult acute myeloid leukemia.

Am J Hematol. 2013 Apr-88(4):306-11. doi: 10.1002/ajh.23403. Epub 2013 Mar 5.

06/11/2020

Boudry-Labis E, Roche-Lestienne C, Nibourel O, Boissel N, Terre C, Perot C, Eclache V, Gachard N, Tigaud I, Plessis G, Cuccuini W, Geffroy S, Villenet C, Figeac M, Leprêtre F, Renneville A, Cheok M, Soulier J, Dombret H, Preudhomme C - French ALFA group.

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.

Blood. 2013 Mar 21 - 121(12):2213-23. doi: 10.1182/blood-2012-10-462879. Epub 2013 Jan 15.

06/11/2020

Jourdan E, Boissel N, Chevret S, Delabesse E, Renneville A, Cornillet P, Blanchet O, Cayuela JM, Recher C, Raffoux E, Delaunay J, Pigneux A, Bulabois CE, Berthon C, Pautas C, Vey N, Lioure B, Thomas X, Luquet I, Terré C, Guardiola P, Béné MC, Preudhomme C, Ifrah N, Dombret H - French AML Intergroup.

Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older.

J Clin Oncol. 2013 Jan 20-31(3):321-7. doi: 10.1200/JCO.2011.40.3642. Epub 2012 Dec 17.

06/11/2020

Gardin C, Chevret S, Pautas C, Turlure P, Raffoux E, Thomas X, Quesnel B, de Revel T, de Botton S, Gachard N, Renneville A, Boissel N, Preudhomme C, Terré C, Fenaux P, Bordessoule D, Celli-Lebras K, Castaigne S, Dombret H.

Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial.

Leuk Res. 2012 Sep-36(9):1112-8. doi: 10.1016/j.leukres.2012.04.020. Epub 2012 May 28.

06/11/2020

Thomas X, Raffoux E, Renneville A, Pautas C, de Botton S, de Revel T, Reman O, Terré C, Gardin C, Chelghoum Y, Boissel N, Quesnel B, Cordonnier C, Bourhis JH, Elhamri M, Fenaux P, Preudhomme C, Socié G, Michallet M, Castaigne S, Dombret H.

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.

Lancet. 2012 Apr 21-379(9825):1508-16. doi: 10.1016/S0140-6736(12)60485-1. Epub 2012 Apr 5.

06/11/2020

Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, Thomas X, Turlure P, Reman O, de Revel T, Gastaud L, de Gunzburg N, Contentin N, Henry E, Marolleau JP, Aljijakli A, Rousselot P, Fenaux P, Preudhomme C, Chevret S, Dombret H - Acute Leukemia French Association.

Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML.

Bone Marrow Transplant. 2012 Nov-47(11):1436-41. doi: 10.1038/bmt.2012.49. Epub 2012 Mar 19.

06/11/2020

Hospital MA, Thomas X, Castaigne S, Raffoux E, Pautas C, Gardin C, Bourhis JH, Reman O, de Revel T, Terré C, Preudhomme C, Fenaux P, Michallet M, Socié G, Dombret H.

Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.

Leukemia. 2012 Jun-26(6):1247-54. doi: 10.1038/leu.2011.382. Epub 2012 Jan 13.

06/11/2020

Renneville A, Boissel N, Nibourel O, Berthon C, Helevaut N, Gardin C, Cayuela JM, Hayette S, Reman O, Contentin N, Bordessoule D, Pautas C, Botton Sd, Revel Td, Terre C, Fenaux P, Thomas X, Castaigne S, Dombret H, Preudhomme C.

Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: a phase 1/2 study of the acute leukemia French association.

Am J Hematol. 2012 Jan-87(1):62-5. doi: 10.1002/ajh.22201. Epub 2011 Nov 10.

06/11/2020

Farhat H, Reman O, Raffoux E, Berthon C, Pautas C, Kammoun L, Chantepie S, Gardin C, Rousselot P, Chevret S, Dombret H, Castaigne S.

Wilms' tumor 1 single-nucleotide polymorphism rs16754 does not predict clinical outcome in adult acute myeloid leukemia.

Leukemia. 2011 Dec-25(12):1918-21. doi: 10.1038/leu.2011.173. Epub 2011 Jul 15.

06/11/2020

Renneville A, Boissel N, Helevaut N, Nibourel O, Terré C, Pautas C, Gardin C, Thomas X, Turlure P, Reman O, Berthon C, Dombret H, Castaigne S, Preudhomme C.

Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study.

Blood. 2011 Aug 18-118(7):1754-62. doi: 10.1182/blood-2011-04-349258. Epub 2011 Jun 20.

06/11/2020

Thomas X, Elhamri M, Raffoux E, Renneville A, Pautas C, de Botton S, de Revel T, Reman O, Terré C, Gardin C, Chelghoum Y, Boissel N, Quesnel B, Hicheri Y, Bourhis JH, Fenaux P, Preudhomme C, Michallet M, Castaigne S, Dombret H.

Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria.

Haematologica. 2011 Jun-96(6):837-44. doi: 10.3324/haematol.2010.036921. Epub 2011 Apr 1.

06/11/2020

Itzykson R, Gardin C, Pautas C, Thomas X, Turlure P, Raffoux E, Terré C, Fenaux P, Castaigne S, Dombret H, Boissel N - Acute Leukemia French Association (ALFA).

Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.

Blood. 2011 Mar 31-117(13):3696-7. doi: 10.1182/blood-2010-11-320937.

06/11/2020

Boissel N, Nibourel O, Renneville A, Huchette P, Dombret H, Preudhomme C.

Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.

J Clin Oncol. 2010 Aug 10-28(23):3717-23. doi: 10.1200/JCO.2010.28.2285. Epub 2010 Jul 12.

06/11/2020

Boissel N, Nibourel O, Renneville A, Gardin C, Reman O, Contentin N, Bordessoule D, Pautas C, de Revel T, Quesnel B, Huchette P, Philippe N, Geffroy S, Terre C, Thomas X, Castaigne S, Dombret H, Preudhomme C.

Prognostic value of minimal residual disease by real-time quantitative PCR in acute myeloid leukemia with CBFB-MYH11 rearrangement: the French experience.

Leukemia. 2010 Jul-24(7):1386-8. doi: 10.1038/leu.2010.112. Epub 2010 May 27.

06/11/2020

Guièze R, Renneville A, Cayuela JM, Abdelali RB, Boissel N, de Botton S, Rubio MT, Mazingue F, Macintyre EA, Cheok M, Sigaux F, Fenaux P, Dombret H, Preudhomme C.

Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.

Blood. 2010 Aug 19-116(7):1132-5. doi: 10.1182/blood-2009-07-234484. Epub 2010 May 20.

06/11/2020

Nibourel O, Kosmider O, Cheok M, Boissel N, Renneville A, Philippe N, Dombret H, Dreyfus F, Quesnel B, Geffroy S, Quentin S, Roche-Lestienne C, Cayuela JM, Roumier C, Fenaux P, Vainchenker W, Bernard OA, Soulier J, Fontenay M, Preudhomme C.

Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study.

Cancer. 2010 Apr 1-116(7):1725-32. doi: 10.1002/cncr.24943.

06/11/2020

Thomas X, Raffoux E, Renneville A, Pautas C, de Botton S, Terre C, Gardin C, Hayette S, Preudhomme C, Dombret H.

Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study.

J Clin Oncol. 2010 Feb 10-28(5):808-14. doi: 10.1200/JCO.2009.23.2652. Epub 2010 Jan 4.

06/11/2020

Pautas C, Merabet F, Thomas X, Raffoux E, Gardin C, Corm S, Bourhis JH, Reman O, Turlure P, Contentin N, de Revel T, Rousselot P, Preudhomme C, Bordessoule D, Fenaux P, Terré C, Michallet M, Dombret H, Chevret S, Castaigne S.

The role of cytogenetic abnormalities in acute myeloid leukemia with NPM1 mutations and no FLT3 internal tandem duplication.

Blood. 2009 Nov 12-114(20):4601-2 - author reply 4602-3. doi: 10.1182/blood-2009-07-230995.

06/11/2020

Micol JB, Boissel N, Renneville A, Castaigne S, Gardin C, Preudhomme C, Dombret H.

Acute myeloid leukemia with translocation (8-21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup.

J Clin Oncol. 2009 Oct 1-27(28):4747-53. doi: 10.1200/JCO.2008.21.0674. Epub 2009 Aug 31.

06/11/2020

Prébet T, Boissel N, Reutenauer S, Thomas X, Delaunay J, Cahn JY, Pigneux A, Quesnel B, Witz F, Thépot S, Ugo V, Terre C, Recher C, Tavernier E, Hunault M, Esterni B, Castaigne S, Guilhot F, Dombret H, Vey N - Acute Leukemia French Association - Groupe Ouest-Est des leucémies et autres maladies du sang (GOELAMS) - Core Binding Factor Acute Myeloid Leukemia (CBF AML) intergroup.

Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association.

Cancer. 2009 Aug 15-115(16):3719-27. doi: 10.1002/cncr.24442.

06/11/2020

Renneville A, Boissel N, Zurawski V, Llopis L, Biggio V, Nibourel O, Philippe N, Thomas X, Dombret H, Preudhomme C.

The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication.

Blood. 2009 May 21-113(21):5090-3. doi: 10.1182/blood-2008-12-194704. Epub 2009 Mar 16.

06/11/2020

Renneville A, Boissel N, Gachard N, Naguib D, Bastard C, de Botton S, Nibourel O, Pautas C, Reman O, Thomas X, Gardin C, Terré C, Castaigne S, Preudhomme C, Dombret H.

Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia.

Haematologica. 2008 Dec-93(12):1806-13. doi: 10.3324/haematol.13309. Epub 2008 Oct 6.

06/11/2020

Malfuson JV, Etienne A, Turlure P, de Revel T, Thomas X, Contentin N, Terré C, Rigaudeau S, Bordessoule D, Vey N, Gardin C, Dombret H - Acute Leukemia French Association (ALFA).

Recurrent in-frame insertion in C/EBPalpha TAD2 region is a polymorphism without prognostic value in AML.

Leukemia. 2008 Mar-22(3):655-7. doi: 10.1038/sj.leu.2404926. Epub 2007 Sep 13.

06/11/2020

Biggio V, Renneville A, Nibourel O, Philippe N, Terriou L, Roumier C, Amouyel P, Cottel D, Castaigne S, Dombret H, Thomas X, Fenaux P, Preudhomme C - French alfa group.

Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial.

Blood. 2007 Jun 15-109(12):5129-35. doi: 10.1182/blood-2007-02-069666. Epub 2007 Mar 6.

06/11/2020

Gardin C, Turlure P, Fagot T, Thomas X, Terre C, Contentin N, Raffoux E, de Botton S, Pautas C, Reman O, Bourhis JH, Fenaux P, Castaigne S, Michallet M, Preudhomme C, de Revel T, Bordessoule D, Dombret H.

Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group.

Leukemia. 2007 Mar-21(3):453-61. doi: 10.1038/sj.leu.2404521. Epub 2007 Jan 25.

06/11/2020

Thomas X, Raffoux E, Botton Sd, Pautas C, Arnaud P, de Revel T, Reman O, Terré C, Corront B, Gardin C, Le QH, Quesnel B, Cordonnier C, Bourhis JH, Elhamri M, Fenaux P, Preudhomme C, Michallet M, Castaigne S, Dombret H.

High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group.

Leukemia. 2007 Jan-21(1):66-71. doi: 10.1038/sj.leu.2404434. Epub 2006 Oct 19.

06/11/2020

Taksin AL, Legrand O, Raffoux E, de Revel T, Thomas X, Contentin N, Bouabdallah R, Pautas C, Turlure P, Reman O, Gardin C, Varet B, de Botton S, Pousset F, Farhat H, Chevret S, Dombret H, Castaigne S.

Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML).

Leukemia. 2006 Jun-20(6):965-70. doi: 10.1038/sj.leu.2404188.

06/11/2020

Boissel N, Leroy H, Brethon B, Philippe N, de Botton S, Auvrignon A, Raffoux E, Leblanc T, Thomas X, Hermine O, Quesnel B, Baruchel A, Leverger G, Dombret H, Preudhomme C - Acute Leukemia French Association (ALFA) - Leucémies Aiguës Myéloblastiques de l'Enfant (LAME) Cooperative Groups.

Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype.

Blood. 2005 Nov 15-106(10):3618-20. doi: 10.1182/blood-2005-05-2174. Epub 2005 Jul 26.

06/11/2020

Boissel N, Renneville A, Biggio V, Philippe N, Thomas X, Cayuela JM, Terre C, Tigaud I, Castaigne S, Raffoux E, De Botton S, Fenaux P, Dombret H, Preudhomme C.

Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy.

Leuk Lymphoma. 2005 Jul-46(7):1007-16. doi: 10.1080/10428190500084837.

06/11/2020

Thomas X, Le Q, Botton Sd, Raffoux E, Chelghoum Y, Pautas C, Dreyfus F, Dhedin N, Vekhoff A, Troncy J, Pigneux A, Revel Td, Reman O, Travade P, Thiebaut A, Guerci A, Elhamri M, Fenaux P, Dombret H, Michallet M.

Allogeneic stem cell transplantation in second rather than first complete remission in selected patients with good-risk acute myeloid leukemia.

Bone Marrow Transplant. 2005 Apr-35(8):767-73. doi: 10.1038/sj.bmt.1704884.

06/11/2020

de Labarthe A, Pautas C, Thomas X, de Botton S, Bordessoule D, Tilly H, de Revel T, Bastard C, Preudhomme C, Michallet M, Fenaux P, Bastie JN, Socié G, Cordonnier C, Dombret H - Acute Leukemia French Association.

Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study.

Blood. 2004 Oct 15-104(8):2467-74. doi: 10.1182/blood-2003-10-3561. Epub 2004 May 13.

06/11/2020

Castaigne S, Chevret S, Archimbaud E, Fenaux P, Bordessoule D, Tilly H, de Revel T, Simon M, Dupriez B, Renoux M, Janvier M, Micléa JM, Thomas X, Bastard C, Preudhomme C, Bauters F, Degos L, Dombret H.

Prognosis of inv(16)/t(16-16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup.

Blood. 2003 Jul 15-102(2):462-9. doi: 10.1182/blood-2002-11-3527. Epub 2003 Mar 20.

06/11/2020

Delaunay J, Vey N, Leblanc T, Fenaux P, Rigal-Huguet F, Witz F, Lamy T, Auvrignon A, Blaise D, Pigneux A, Mugneret F, Bastard C, Dastugue N, Van den Akker J, Fière D, Reiffers J, Castaigne S, Leverger G, Harousseau JL, Dombret H - French Acute Myeloid Leukemia Intergroup - Groupe Ouest-Est des Leucémies Aiguës Myéoblastiques - Leucémies Aiguës Myéoblastiques de l'Enfant - Acute Leukemia French Association - Bordeaux-Grenoble-Marseille-Toulouse cooperative groups.

Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA).

Blood. 2002 Oct 15-100(8):2717-23. doi: 10.1182/blood-2002-03-0990.

06/11/2020

Preudhomme C, Sagot C, Boissel N, Cayuela JM, Tigaud I, de Botton S, Thomas X, Raffoux E, Lamandin C, Castaigne S, Fenaux P, Dombret H - ALFA Group.

Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy.

Leukemia. 2002 Sep-16(9):1699-704. doi: 10.1038/sj.leu.2402622.

06/11/2020

Boissel N, Cayuela JM, Preudhomme C, Thomas X, Grardel N, Fund X, Tigaud I, Raffoux E, Rousselot P, Sigaux F, Degos L, Castaigne S, Fenaux P, Dombret H.

A white blood cell index as the main prognostic factor in t(8-21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup.

Blood. 2002 May 15-99(10):3517-23. doi: 10.1182/blood.v99.10.3517.

06/11/2020

Nguyen S, Leblanc T, Fenaux P, Witz F, Blaise D, Pigneux A, Thomas X, Rigal-Huguet F, Lioure B, Auvrignon A, Fière D, Reiffers J, Castaigne S, Leverger G, Harousseau JL, Socié G, Dombret H.